TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Regado Biosciences Inc (NASDAQ: RGDO) Investor Securities Class Action Lawsuit 07/10/2014

  • If you purchased shares of Regado Biosciences Inc (NASDAQ: RGDO), you might have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Regado Biosciences Inc
Security
NASDAQ: RGDO

Case Name
Regado Biosciences Shareholder Class Action Lawsuit 07/10/2014
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the District of New Jersey

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Regado Biosciences Inc.
Summary

December 10, 2014 - The court granted the stipulation.
December 9, 2014 - The parties filed a stipulation of dismissal without prejudice.

September 26, 2014 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.

September 9, 2014 - All cases were consolidated.

September 8, 2014 - Lead plaintiff motions were filed.

July 11, 2014 - Another investor filed a complaint in the U.S. District Court for the District of New Jersey on behalf of investors who purchased Regado Biosciences Inc (NASDAQ: RGDO) common shares between August 22, 2013 and July 2, 2014.

July 10, 2014 - An investor in shares of Regado Biosciences Inc (NASDAQ: RGDO) filed a lawsuit in the U.S. District Court for the District of New Jersey against Regado Biosciences Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between August 22, 2013 and July 9, 2014.

According to the complaint the plaintiff alleges on behalf of purchasers of Regado Biosciences Inc (NASDAQ: RGDO) common shares between August 22, 2013 and July 9, 2014, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that the defendants made allegedly false and/or misleading statements and/or failed to disclose that the danger and frequency of allergic reactions experienced by subjects in the REG1 Phase 3 trial were significant enough to derail the trial, that the allergic reactions were of such a serious nature and/or frequency that the Data Safety Monitoring Board ( DSMB ) and FDA would ultimately be required to place the clinical trial on hold, and that and as a result of the above, Regado Biosciences Inc's financial statements were allegedly materially false and misleading at all relevant times.

Regado Biosciences Inc reported that its Net Loss increased from $13.06 million in 2012 to $34.44 million in 2013. Shares of Regado Biosciences Inc (NASDAQ: RGDO) grew from $4.53 per share in September 2013 to as high as $13.50 per share in March 2014.

Then on July 2, 2014 Regado Biosciences Inc, announced, among other things, that the Data Safety Monitoring Board, or DSMB, has initiated an unplanned review of data from Regado Biosciences Inc's Phase 3 trial of Revolixys Kit (previously known as REG1), entitled REGULATE-PCI, and that patient enrollment has been paused in the REGULATE-PCI trial until the DSMB has completed its analysis and communicated its recommendations. Shares of Regado Biosciences Inc (NASDAQ: RGDO) dropped from $6.99 per share on July 2, 2014, to as low as $2.70 per share during July 3, 2014 and continued to declined to as low as $2.43 per share on July 10, 2014.